SCHEMBL20119503

SCHEMBL20119503

CCCCOc1nc2c(NCc3ccncc3)nc(Cl)nc2[nH]1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 3/20 0.40
CCNE1 P24864 2/20 0.40
CCNE2 O96020 1/20 0.40
PDE4A P27815 2/20 0.40
PDE4B Q07343 2/20 0.40
PDE4C Q08493 2/20 0.40
PDE4D Q08499 2/20 0.40
PDE3B Q13370 2/20 0.40
PDE3A Q14432 2/20 0.40
LMNA P02545 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CDK1 P06493 3/20 0.38
CTSL P07711 3/20 0.38
KDM4E B2RXH2 1/20 0.38
HPGD P15428 1/20 0.38
PGK1 P00558 1/20 0.37
PDE5A O76074 1/20 0.37
PDE10A Q9Y233 1/20 0.36
YTHDC1 Q96MU7 1/20 0.36
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20119611 0.94 CDK1 (0.39) CDK2CCNE1CCNE2PDE4APDE4B
SCHEMBL20119867 0.90 CDK2 (0.40) CDK2CCNE1CCNE2CDK1CTSL
SCHEMBL20119522 0.90 CDK1 (0.40) CDK2CCNE1CCNE2PDE4APDE4B
SCHEMBL20119916 0.89 CCNE1 (0.40) CDK2CCNE1CCNE2CDK1CTSL
SCHEMBL20119530 0.88 CDK1 (0.37) CDK2CCNE1CCNE2CDK1CTSL
SCHEMBL20119907 0.85 CCNE2 (0.44) CDK2CCNE1CCNE2CDK1PGK1
SCHEMBL20119728 0.82 CCNE2 (0.41) CDK2CCNE1CCNE2CDK1PDE5A
SCHEMBL20119546 0.82 CDK2 (0.36) CDK2CCNE1CCNE2LMNACDK1
SCHEMBL20119456 0.82 CDK1 (0.40) CDK2CCNE1CCNE2CDK1PGK1
SCHEMBL20119759 0.81 HRH4 (0.35) CDK2CCNE1CCNE2PDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 CDK2 3622/4885CCNE1 4220/4885CCNE2 4321/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 CDK2 3622/4885CCNE1 4220/4885CCNE2 4321/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 CDK2 3622/4885CCNE1 4220/4885CCNE2 4321/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 CDK2 3622/4885CCNE1 4220/4885CCNE2 4321/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 CDK2 3622/4885CCNE1 4220/4885CCNE2 4321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.